Marinomed Biotech AG Forms Strategic Partnership for Marinosolv® in Inhalation Therapy

Marinomed Biotech AG has signed a term sheet for a strategic partnership with Phargentis SA, granting a worldwide exclusive license for its Marinosolv® technology platform. This agreement marks a significant expansion into inhalation therapy, enhancing solubility and bioavailability of hydrophobic compounds for respiratory treatments.

The financial structure includes immediate development fees, milestone payments, and future royalties on product sales. The collaboration will utilize Marinomed's expertise to develop a high-performance inhalation formulation with various active pharmaceutical ingredients.

This partnership is a step towards monetizing Marinomed's technology beyond its internal pipeline, highlighting its potential across multiple therapeutic areas, especially where drug solubility is a barrier to success.